<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2036">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134662</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-801-104</org_study_id>
    <nct_id>NCT05134662</nct_id>
  </id_info>
  <brief_title>ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability, Pharmacodynamics and Pharmacokinetics of ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to&#xD;
      evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of&#xD;
      ALT-801 and its effects on glucose control in overweight and obese subjects with type 2&#xD;
      diabetes mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 110</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in area under the curve of serum glucose, C-peptide, and insulin</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in fasting serum glucose and insulin as measured by Homeostasis Model Assessment for Insulin Resistance 2 (HOMA-IR2)</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting serum glucose</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in quality of life questionnaires compared to baseline</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ALT-801 concentrations</measure>
    <time_frame>Baseline to Day 110</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline metformin concentrations</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ALT-801 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALT-801 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALT-801 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-801</intervention_name>
    <description>Injected subcutaneously (SC)</description>
    <arm_group_label>ALT-801 Dose Level 1</arm_group_label>
    <arm_group_label>ALT-801 Dose Level 2</arm_group_label>
    <arm_group_label>ALT-801 Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injected subcutaneously (SC)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent signed prior to the performance of any study procedures&#xD;
&#xD;
          -  Male or female volunteers, age 18 to 65 years, inclusive&#xD;
&#xD;
          -  Overweight to obese (BMI 28.0 - 40.0 kg/m2)&#xD;
&#xD;
          -  Type 2 diabetes mellitus (T2DM), on stable regimen, for at least 3 months prior to&#xD;
             screening, of any combination of (1) diet and exercise, (2) metformin with absent or&#xD;
             mild gastrointestinal symptoms (nausea, vomiting or diarrhea), and/or (3) sodium&#xD;
             glucose cotransporter-2 (SGLT-2) therapy&#xD;
&#xD;
          -  Female subjects of childbearing potential who are not pregnant or breastfeeding, do&#xD;
             not plan to become pregnant during the study, and agree to use effective birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus (DM) and/or insulin-dependent T2DM, or uncontrolled T2DM&#xD;
             defined as hemoglobin A1c (HbA1c) ≥ 9.5% or C-peptide ≤ 8 ng/mL&#xD;
&#xD;
          -  History of acute or chronic pancreatitis or hypersensitivity reaction to GLP-1&#xD;
             analogues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Altimmune CTM</last_name>
    <phone>2406541450</phone>
    <email>information@altimmune.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obese</keyword>
  <keyword>Overweight</keyword>
  <keyword>T2DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

